Tarsus Pharmaceuticals Relocates Principal Offices

TL;DR

Tarsus Pharma moving HQ to Irvine, CA. New address: 15440 Laguna Canyon Rd, Ste 160.

AI Summary

Tarsus Pharmaceuticals, Inc. announced on January 15, 2025, a change in its principal executive offices to 15440 Laguna Canyon Road, Suite 160, Irvine, CA 92618. The company also updated its principal business address to the same location. This filing is a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934.

Why It Matters

A change in principal executive offices can indicate growth, consolidation, or strategic shifts within a company, potentially impacting operational efficiency and employee location.

Risk Assessment

Risk Level: low — This filing primarily concerns a change of address for the company's principal executive offices, which is a routine administrative update.

Key Players & Entities

• Tarsus Pharmaceuticals, Inc. (company) — Registrant
• 15440 Laguna Canyon Road, Suite 160, Irvine, CA 92618 (location) — New Principal Executive Offices and Business Address
• January 15, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share TARS The Nasdaq Sto

Filing Documents

• tars-20250115.htm (8-K) — 23KB
• 0001819790-25-000003.txt ( ) — 143KB
• tars-20250115.xsd (EX-101.SCH) — 2KB
• tars-20250115_lab.xml (EX-101.LAB) — 21KB
• tars-20250115_pre.xml (EX-101.PRE) — 12KB
• tars-20250115_htm.xml (XML) — 3KB

02. Departure of Directors or Certain Officers

Item 5.02. Departure of Directors or Certain Officers On January 15, 2025, Rosemary Crane, a member of the Board of Directors (the "Board") of Tarsus Pharmaceuticals, Inc. (the "Company") notified the Company of her resignation as a member of the Board and any committees of the Board, effective January 17, 2025. The resignation is not a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. Effective January 17, 2025, the Company entered into a consulting agreement with Ms. Crane (the "Consulting Agreement") under which Ms. Crane will serve as a consultant to the Company. Ms. Crane will be eligible to continue to vest in her outstanding equity awards subject to her continuous service pursuant to the Consulting Agreement. The Consulting Agreement has an initial term of 6 months unless terminated earlier pursuant to its terms. The Consulting Agreement contains standard confidentiality, indemnification and intellectual property assignment provisions in favor of the Company. Further, on January 16, 2025, based on the recommendation of the Board's Nominating and Corporate Governance Committee, the Board authorized and approved the appointment of Wendy Yarno, the Company's Lead Independent Director and current member of the Board, as Chairperson of the Commercial Committee of the Board, the transition of Ms. Yarno off the Audit Committee of the Board and the appointment of Andrew Goldberg, M.D., current member of the Board, as a member of the Audit Committee of the Board, each effective as of January 17, 2025.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TARSUS PHARMACEUTICALS, INC. Date: January 17, 2025 /s/ Bryan Wahl Bryan Wahl General Counsel and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR